Premium Nahrungsergänzungsmittel | artgerecht

Prostate Health Markers – Biomarkers Explained

Prostate health markers are medical biomarkers measured in blood or urine that provide information about the condition of the prostate and support early detection of prostate diseases.

Regular tips about health Regular tips about health

Things worth knowing about "Prostate Health Markers"

Prostate health markers are medical biomarkers measured in blood or urine that provide information about the condition of the prostate and support early detection of prostate diseases.

What Are Prostate Health Markers?

Prostate health markers are biological indicators – known as biomarkers – measured in blood, urine, or tissue to assess the health of the prostate gland. They help physicians detect, monitor, and manage conditions such as prostate cancer, benign prostatic hyperplasia (BPH), and prostatitis (inflammation of the prostate) at an early stage.

The Most Important Prostate Health Markers

PSA – Prostate-Specific Antigen

The most widely used prostate health marker is Prostate-Specific Antigen (PSA). PSA is a protein produced exclusively by the prostate gland and can be detected in the blood. Elevated PSA levels may indicate prostate cancer, but can also result from benign enlargement or inflammation of the prostate. The PSA test is used as a screening tool but is not a definitive indicator of cancer on its own.

Normal range: Generally below 4 ng/ml, depending on the patient's age
Free PSA: The ratio of free to total PSA can help differentiate benign from malignant conditions
PSA density and PSA velocity: Additional measures used to better interpret PSA readings

PCA3 – Prostate Cancer Antigen 3

PCA3 is a urine-based marker that is more specific to prostate cancer than PSA. It is often used when PSA levels are elevated but a previous biopsy was negative. PCA3 helps reduce the number of unnecessary repeat biopsies.

phi – Prostate Health Index

The Prostate Health Index (phi) combines three PSA forms (total PSA, free PSA, and [-2]proPSA) into a single value. It provides a more accurate assessment of cancer risk than PSA alone and helps minimize unnecessary biopsies.

4Kscore Test

The 4Kscore test measures four kallikrein markers in the blood (total PSA, free PSA, intact PSA, and human kallikrein 2) to calculate an individual's risk of aggressive prostate cancer. It is used as a complement to the standard PSA test.

Additional Markers

Testosterone: The primary male sex hormone that influences prostate growth and plays a role in hormone-dependent prostate conditions
PSMA (Prostate-Specific Membrane Antigen): Increasingly used in imaging and as a target for novel therapies in prostate cancer
SelectMDx and IsoPSA: Newer urine-based and blood-based biomarker tests for improved risk stratification

When Are Prostate Health Markers Used?

Prostate health markers are applied in a variety of clinical situations:

Early detection of prostate cancer as part of routine screening
Evaluation of symptoms such as frequent urination, weak urine flow, or pelvic pain
Monitoring disease progression during or after treatment for prostate cancer
Surveillance following radical prostatectomy (surgical removal of the prostate)
Detection of biochemical recurrence after treatment

Diagnosis and Interpretation

No single marker is sufficient on its own for a reliable diagnosis. Values are always interpreted in the context of the patient's age, medical history, the result of a digital rectal examination (DRE), and imaging methods such as prostate MRI. When clinical suspicion is high, a prostate biopsy may be required to confirm the diagnosis.

Importance for Preventive Healthcare

Regular monitoring of prostate health markers – particularly from the age of 50 onwards (or from age 40 for those at higher risk, such as those with a family history of prostate cancer) – can help detect prostate diseases at an early, more treatable stage. The decision for or against screening should always be made in consultation with a physician, as a careful consideration of benefits and potential risks (such as overdiagnosis) is necessary.

References

European Association of Urology (EAU) – EAU Guidelines on Prostate Cancer (2023). Available at: https://uroweb.org/guidelines/prostate-cancer
Catalona, W.J. et al. – Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer from Benign Prostatic Disease. JAMA, 279(19):1542-1547 (1998).
Loeb, S. et al. – Prostate Health Index selectively identifies clinically significant prostate cancer. Journal of Urology, 193(4):1163-1169 (2015).

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category